IL-8 has been reported to be a prognostic factor in patients undergoing immune checkpoint inhibitor (ICI) treatment for malignant melanoma, lung cancer, and renal cell carcinoma [7–10], and high levels of IL-6 may be useful in predicting treatment response in HCC treated with Atezo+Bev therapy [5, 6]. Here, CXCL8 is linked to hepatocellular carcinoma.